Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Heslop, Helen E  [Clear All Filters]
Journal Article
Hill LQC, Rouce RH, Wu M, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, et al. Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas. Blood. 2023.
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, et al. Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Yang X, Zhang M, Ramos C, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, et al. Closely-related T-memory stem cells correlate with in-vivo expansion of CAR.CD19-T cells in patients and are preserved by IL-7 and IL-15. Blood. 2014.
Streck BParmelee, Naufal G, Carrum G, Hill LQ, Heslop HE, Ramos CA, Kamble R, Cohen M, East K, Sena M, et al. Demographic and Clinical Donor Characteristics as Predictors of Total Nucleated Cell Concentrations in Harvested Marrow Products. Transplant Cell Ther. 2021.
Mo F, Watanabe N, Omdahl KIngersoll, Burkhardt PM, Ding X, Hayase E, Panoskaltsis-Mortari A, Jenq RR, Heslop HE, Kean LS, et al. Engineering T cells to suppress acute GvHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2022.
Heslop HE, Shpall EJ. HARMONIZING IMMUNE EFFECTOR TOXICITY REPORTING. Biol Blood Marrow Transplant. 2019.
Saldaña BJDávila, John TD, Bonifant CL, Buchbinder D, Chandra S, Chandrakasan S, Chang W, Chen L, Elfassy HL, Geerlinks AV, et al. High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2021.
Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015.
Russell Y Cruz C, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, A Barrett J, Ito S, et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. Blood. 2013.
Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2013.
Zhou X, Di Stasi A, Tey S-K, Krance RA, Martinez C, Leung KS, Durett AG, Wu M-F, Liu H, Leen AM, et al. Long-term outcome and immune reconstitution after haploidentical stem cell transplant in recipients of allodepleted-T-cells expressing the inducible caspase-9 safety transgene. Blood. 2014.
Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai S-Y, Rowley SD, Kebriaei P, et al. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013.
Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales M-A, Kebriaei P, Warkentin PIrene, Pasquini M, Aho JLynn, et al. Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. Transplant Cell Ther. 2023.
Naik S, Riches M, Hari P, Soyoung K, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, et al. Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. Transpl Infect Dis. 2019:e13145.